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Abstract 
DNA nanotechnology is an emerging and exciting field, and represents a forefront frontier for the 
biomedical field. The specificity of the interactions between complementary base pairs makes 
DNA an incredible building material for programmable and very versatile two- and 
three-dimensional nanostructures called DNA origami. Here, we analyze the DNA origami and 
DNA-based nanostructures as a drug delivery system. Besides their physical-chemical nature, we 
dissect the critical factors such as stability, loading capability, release and immunocompatibility, 
which mainly limit in vivo applications. Special attention was dedicated to highlighting the bounda-
ries to be overcome to bring DNA nanostructures closer to the bedside of patients. 
Key words: Nanomedicine, Nanotechnology, Cancer, Drug delivery, Doxorubicin, Self-assembly, DNA, Ori-
gami.
Introduction 
The delivery of drug molecules specifically to the 
tumor site is an exigent requirement to avoid side 
effects during cancer therapy. However, this 
requirement is still clinically unmet, mainly due to the 
lack of effective drug delivery systems (DDSs) for 
single or combinatorial chemotherapy. In the last two 
decades, various organic and/or inorganic 
nanomaterials have been used to create 
nanostructures that facilitate anticancer drug delivery 
[1]. In particular, nanoparticle-based DDSs have been 
shown to enhance permeability and retention (EPR) 
effects, leading to passive tumor drug accumulation 
[1]. However, in some cases the observed toxicity 
versus normal tissues raised concerns over real 
applications in humans [2–4]. Recently, many 
research groups have focused their attention on DNA 
material for the construction of artificial 
nanostructures not present in biological systems for 
bio-applications [5–8]. DNA, being a genetic material, 
possesses high biocompatibility and low cytotoxicity 
ideal for applications in the biomedical field [5,9]. Its 
remarkable molecular recognition properties, and 
complementary base pairing, along with its stability, 
mechanical rigidity, nano-dimensions of the repeating 
unit, easily custom synthesis with manipulative 
length of strands allow the formation of most every 
shape of nanostructures. Moreover, high drug loading 
efficiency and effective cellular internalization further 
support DNA origami as a programmable “smart” 
building block for the construction and development 
of versatile highly nontoxic drug nanocarriers 
[5–7,9,10]. The highly-controllable DNA origami 
nanostructures with addressable modification sites, 
simple loading methods for biomolecules, 
biocompatibility and biodegradability, offer many 
advantages to be ideal targeted drug delivery 
comparing to the delivery systems such as liposomes 
and polymeric nanoparticles which have already been 
approved for clinical use [11–15]. 
Due to the aforementioned properties, DNA 
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nanostructures have been synthesized and engineered 
for various applications, such as: i) scaffolds or 
templates to arrange organic, inorganic and 
biomolecules into defined morphology; ii) molecular 
transporters; iii) highly sensitive molecular- and 
bio-detector; iv) single molecule spectroscopy; v) 
protein structure determination, and vi) vehicles for 
in vitro and in vivo drug delivery [16].  
In the present review, we will briefly introduce 
the properties of DNA and its structure in various 
self-assembled arrangements to guide readers 
through the topic of the review focused mainly on the 
recent advances on the biomedical applications of 
DNA nanostructures, particularly, their potential as 
nanocarriers of drug and other molecules across the 
cellular membrane for specific and effective drug 
delivery to cancerous cells.  
Former DNA nanostructures  
The physical and chemical properties of DNA 
nanostructures are reported in excellent recently 
published reviews [17–19]. Here, we describe the 
basic elements that are useful to understand the 
self-assembled DNA nanostructure as drug 
nanocarriers. The pyrimidine and purine bases that 
constitute the nucleotides in single-stranded DNA are 
linked to pentose sugar and this latter associated unit 
is called a nucleoside, which is connected to another 
nucleoside through the phosphodiester bond. The 
asymmetric ends of DNA strands are called the 5' and 
3' ends depending on whether the terminal group is a 
phosphate group or a free hydroxyl group, 
respectively. The purine bases are classified into two 
types: Adenine (A) and Guanine (G). They have a 
structure derived from the fusion of five- and 
six-membered heterocyclic structure, while the 
pyrimidines are Cytosine (C) and Thymine (T) and are 
six-membered ring (Figure 1A).  
In B-form dsDNA, the most common form of 
double helix, two nucleotide nanowires are twisted 
around each other with a replicate unit every 3.4 nm 
while maintaining a distance of 3.4 Å between the 
consecutive base pairs in a double helix with a 
diameter of 2 nm (Figure 1B). The twist angle between 
base pairs in solution is ~34.38º with C2'-endo sugar 
pucker. The persistence length of dsDNA, which is a 
measure of stiffness, is very close to 50 nm if the 
concentration of NaCl exceeds 10 mM or the 
concentration of MgCl2 exceeds 0.5 mM. It was found 
that the dsDNA persistence length in a solution 
containing 10 mM MgCl2 is equal to 47±1 nm.  
 
Figure 1. A) Adenine (A), Thymine (T), Cytosine (C) and Guanine (G) of DNA responsible for the robust complementary base pair interactions between DNA strands. B) Key 
features of DNA structures. C) Chemical structure of DNA stabilized by hydrogen bonds between the bases A-T and G-C. Copyright 2002, Pearson Education, Inc. Publishing 
as Benjamin Cummings. 
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Many theoretical and experimental studies were 
dedicated to the dependence of persistence length on 
ionic conditions, and it seems that the persistence 
length is practically independent of ionic 
concentrations if the concentration of NaCl > 10mM 
or the concentration of MgCl2 > 0.5 mM [20,21]. Two 
factors are mainly responsible for the stability of the 
geometry of the DNA double helix: the presence of 
hydrogen bonds between complementary bases of the 
strands, and aromatic π-π stacking between adjacent 
bases. Two hydrogen bonds are formed between the 
bases A and T and three between G and C attached to 
the two strands (Figure 1C). While each hydrogen 
bond is weak compared to a covalent bond, a large 
number of hydrogen bonds together represent a 
strong force that keeps the two strands bound. In 
addition, other polar groups of the base rings can 
form external hydrogen bonds with surrounding 
water that give to the molecule extra stability. The 
hydrogen bond is not the only force that gives 
stability to the dsDNA structure. The negatively 
charge of the phosphate group can interact with 
positively charged atoms with electrostatic forces [22]. 
The free energy contribution (-ΔG/kcal mol-1) of the 
formation of A-T and G-C base pairs due to hydrogen 
bonds is ~1.34 and 2.17, respectively [23]. 
A DNA nanostructure is a bottom-up assembly 
of multiple ssDNA that have to hybridize to other 
segments or to a scaffold. In 1964, Robin Holliday 
illustrated a four-armed DNA branched junction, 
which later became known as the Holliday junction, 
in which four DNA strands are linked together to 
form four double helical arms flanking a branch point. 
A Holliday junction occurs commonly in nature, as it 
is being the process of genetic recombination called 
crossing-over involving in passing genetic diversity to 
the next generation. This specific genetic structure 
became the foundation of DNA nanotechnology, in 
which by connecting several Holliday junctions in the 
form of tiles and yielded DNA lattice in two and three 
dimensions [24]. The DNA double crossover (DX) 
molecule is characterized by the crossover of a DNA 
strand that exchanges between two strands of 
opposite polarity [25,26]. This enables robust 
connections among several DNA helices. A DX DNA 
tile is a DNA nanostructure that has a number of 
sticky ends on its sides, which are termed pads. A 
sticky end is a short ssDNA or hang protruding 
strand from the end of a DNA helix. A DNA lattice is 
a DNA nanostructure composed of a group of DNA 
tiles that are assembled together via hybridization of 
their pads.  
One more modification is the three-domain 
DNA triple crossover (TX) complex that connects 
three DNA helix axes by one strand in one plane [16]. 
Using rigid DX or TX tiles, regular two-dimensional 
arrays could be created by sticky-ended cohesion of 
several molecules (Figure 2) [27]. Multiple crossovers 
could also be created which leads to the formation of 
more sophisticated structures.  
 
 
Figure 2. Schematic drawings of four DNA tiles are shown. Colored lines represent 
different oligonucleotide strands with arrowheads marking the 3 ends. DAE and DAO 
are double crossover complexes (also known as DX), TAO is an example of a triple 
crossover (or TX) tile, and the 4 × 4 tile is composed of four arms each of which 
contains a four-arm junction. Reproduced with permission from reference [27].  
 
DNA origami  
DNA nanotechnology uses the molecular 
recognition properties of DNA to create artificial 
DNA structures for technological purposes. It holds 
great promise for a vast range of applications in 
different fields such as biology, medicine and material 
science. In 1982, Nadrian Seeman laid the theoretical 
framework for the use of DNA as a nanoscale 
building material. This is due to the DNA's capacity 
for programmable self-assembly and its high stability 
[24,28]. 
In 2006, Paul Rothemund at the California 
Institute of Technology introduced the term 
“scaffolded DNA origami”, which has revolutionized 
the field of structural DNA nanotechnology by 
enhancing the complexity and size of self-assembled 
DNA nanostructures in a simple “one-pot” reaction 
(Figure 3A) [29]. 
Scaffolded DNA origami involves the folding of 
a long circular single-strand-scaffold viral DNA 
derived from the bacteriophage M13mp18 composed 
of 7249 nucleotide sequences with hundreds of short 
staple strands or helper strands of DNA into the 
desired shape. The DNA origami technique has been 
successfully used for the preparation of different 2D 
and 3D nanostructures and for the nanopatterning of 
nanoparticles, proteins and other functional 
molecular components into well-defined 
arrangements (Figure 4) [30]. Chemically modified 
staples can be inserted at a predefined position in the 
DNA nanostructure, which could be used to impart 
several additional functionalities in the designed 
DNA nanostructures. The design of a DNA origami is 
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then fed into computer software called “caDNAno” 
which calculates the placement of individual staple 
strands [31]. Each staple binds to a specific region of 
the DNA template due to Watson-Crick base pairing 
rules. The scaffold strand and the staple strands are 
mixed in a one-pot reaction and rapid heating 
followed by slow cooling allows the various staple 
strands to pull the long scaffold strand into the 
desired shape. More recently, many groups invented 
a versatile strategy that could reliably manipulate the 
DNA conformation and shape of the crossover 
networks to design 2D and 3D nanostructures twisted 
and curved, for example, spherical shells, ellipsoid 
shells and nanoflask (Figure 3B) [32–34]. Further, they 
utilized a series of four-arm junctions to create 
gridiron-like DNA nanostructures, which involves 
stacking multiple layers of 2D gridiron lattices to form 
multilayer 3D nanostructures and curved objects 
(Figure 3C) [35]. Wei et al. and Ke et al. developed a 
new strategy, which combines the advantages of tile 
and origami assembly utilizing single-stranded 
tiles/bricks with concatenated sticky ends as building 
blocks to form 2D and 3D DNA canvas (Figure 3D) 
[36,37]. In a different line, Benson et al. developed a 
method highly automated by using a routeing 
algorithm based on graph theory and relaxation 
simulation that traces scaffold strands through the 
target structures. These structures have one helix per 
edge and are stable under the ionic condition of 
biological assays (Figure 3C) [38]. 
The design concept of DNA origami, their shape 
and assembly principles was discussed by Linko and 
Dietz [39] and Castro et al. and it is illustrated in 
Figure 5 [40]. The double helix structure of DNA is 
represented as double helix domains (cylindrical 
representation) for designing purposes (Figure 5A). 
Double helix domains are connected to adjacent 
double helix domains by multiple interhelix 
connections consisting of immobilized Holliday 
junctions [25]. As shown in Figure 5B, the interhelix 
connections are formed by antiparallel crossovers of 
either the staple or scaffold strand. 
 
 
Figure 3. In DNA origami: A) a long circular single-strand DNA scaffold is folded into a desired shape with the aid of hundreds of short staple strands. In the above example, 
circular single-stranded genome of M13 bacteriophage (M13mp18) is folded with the assistance of about 200 staple strands into a DNA nanocube with dimension of 35x36x42 
nm during a thermal annealing process. Adapted with permission from reference [29]. B) 3D structure with complex curvatures. Adapted with permission from reference [33]. 
C) DNA gridiron nanostructures. Reproduced with permission from references [35,38]. D) Design of 2D and 3D DNA canvas using single-stranded tiles/bricks. Adapted with 
permission from references [36,37]. 
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Figure 4. The first examples of the versatile DNA Origami technique. Top row, 
folding paths. A, square; B, rectangle; C, star; D, disk with three holes; E, triangle 
with rectangular domains; F, sharp triangle with trapezoidal domains and bridges 
between them (red lines in inset). Dangling curves and loops represent unfolded 
sequence. The lower panels contain the resulting DNA structures as imaged by AFM. 
All images and panels without scale bars are the same size, 165 nm x165 nm. Scale 
bars for lower AFM images: B, 1 µm; C–F, 100 nm. Reproduced with permission 
from reference [30]. 
 
 
Figure 5. Scaffold DNA origami design concept: A) Schematic representation of 
DNA double helices. B) Two double helices are connected by interhelix crossovers. 
C) Scaffold strand routing to form three different DNA origami objects. D) For the 
same three DNA nanostructures, staples are highlighted with different colors to form 
the structures. E) Cylindrical representation of the three DNA nanostructures. 
Reproduced with permission from reference [40]. 
 
A step-by-step guide to building DNA origami 
objects is shown in Figure 6 [40]. 
Step 1: Conceive target shape. The work starts with 
the conception of a target shape with specific 
functional requirements. Based on the application, it 
is important to decide on a single-layer or multilayer 
structure using square lattice or honeycomb lattice. In 
Figure 6, Step 1, a 72 nm-tall sculpture of a robot is 
considered as the target shape using a multilayer 
honeycomb lattice packing. 
Step 2: Design layout, evaluate design and determine 
staple sequences. The designing of the internal layout of 
the DNA origami object can be accomplished with 
many computational tools (Figure 6, Step 2). Based on 
crossover spacing rules, the staple sequence can be 
determined. Certain applications require site-directed 
attachment of nanoparticles, proteins or fluorescent 
dyes. Such attachments need to be considered in this 
scaffold-staple layout. 
After designing the layout, it is very important to 
validate the designed DNA nanostructure in order to 
realize their mechanical flexibility and topology by 
simulating their twists, bends, curvatures and 
fluctuations and rigidity in a solution using a 
computational tool named computer-aided 
engineering for DNA origami (CanDo) [40–42]. 
Step 3: Prepare scaffold DNA and synthesize staples. 
The quality of DNA origami folding might depend on 
the scaffold sequence and the particular cyclic 
permutation, which means the repeating units of the 
targeted shape. The single-stranded M13mp18 
bacteriophage genome is used as long scaffold strand, 
which acts as a template for scaffolded DNA origami. 
This template is commercially available. The scaffold 
strand could also be prepared by an enzymatic [43] or 
by a denaturing dialysis method to separate a dsDNA 
(derived from M13mp18) into two ssDNA scaffolds 
[44]. The staple sequences, which are generated while 
designing the DNA origami, are utilized to synthetize 
the desired oligonucleotides. 
Step 4: Pool subsets of concentration-normalized 
oligonucleotides. This step is important in deciding the 
right concentration ratio of scaffold strand to staple 
molecules. For optimal results, this ratio is usually set 
at 1:5. 
Step 5: Run molecular self-assembly reactions. One 
theory is that the scaffold-staple layout requires a 
structural solution for the correct mixture of scaffold 
DNA and staple molecules that minimizes energy 
through Watson-Crick base pairing. The targeted 
shape corresponds to a global energy minimum of the 
system and depends on the solvent and design 
conditions. The goal of the self-assembly reaction is to 
reach a minimum energy state in conditions where the 
targeted structure is folded. The best conditions are 
identified as a function of the salt concentration and 
cyclic temperatures. 
The experimental conditions for the assembly of 
various DNA nanostructures such as scaffold to 
staples ratio, buffer, salt concentrations and annealing 
temperature are of paramount importance for their 
correct folding, structural integrity and yield. A 1:5 to 
1:10 ratio of scaffold to staples is enough for the 
self-assembly reaction. For most of the folding 
reaction a buffer containing 10 to 25 mM of Mg2+ in 
1xTE, depending of the layers, length and shape of the 
DNA-origami structure, is adequate. It has been 
shown that a monovalent ion (Na+) could also be used 
in place of divalent ion (Mg2+) for DNA-origami 
preparation, however a very high concentration of 
Na+ is required [45]. For annealing, the mixture of 
scaffold and staples in folding buffer is heated to 90 
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°C and then slowly cool down to 4 °C and this step 
usually takes up to a week. Dietz and coworker 
showed that folding occurs in a very narrow 
temperature range of 60 °C - 45 °C, which has 
drastically slashed the annealing to few hours [46]. 
Step 6: Analyze folding quality and purify the object. 
The quality assessment of DNA origami folding and 
purification could be accomplished by gel 
electrophoresis. The gel has to contain magnesium 
during running. The reactions could be optimized by 
searching for the best conditions, which give a high 
yield of nanostructures and good gel separation from 
the staples. The reactions are purified from the gel 
slabs by excising the desired bands followed by the 
DNA electro-elution method [47]. Another method 
used to purify and concentrate DNA developed by 
Stahl et al. is based on polyethylene glycol (PEG) 
precipitation with high molecular weight. This 
method was efficient and used to reduce the elution 
volumes and achieve high recovery yields of up to 
97% [48]. Ultrafiltration method consists in a 
repetitive dilution-concentration process across a 
regenerated cellulose membrane, which retains the 
large DNA origami structures while the small 
contaminants flow through [49]. Gel filtration utilizes 
various dextran or agarose-based size exclusion resins 
in spin columns to retain contaminants while DNA 
origami structures flow through during centrifugation 
[50]. The purification could be also achieved using 
rate-zonal ultracentrifugation on glycerol density 
gradient where DNA origami are separated by 
density. This method allowing for larger quantities of 
DNA nanostructures to be purified, with less time and 
effort. The recovery yield is between 40-80% [51].  
Due to the difficulties in purifying 
functionalized DNA origami, in particular with 
proteins, Shaw et al. investigated the efficiency of 
different methods. The authors adapted two methods: 
magnetic bead captures and fast protein liquid 
chromatography (FPLC). FPLC is commonly used to 
purify DNA or proteins on a Superose column. This 
technique is indicated for origami purification since 
the reaction can be performed in a variety of 
physiological buffers. The recovery yield is around 
70% [49]. 
 
 
Figure 6. Step-by-step guide of molecular self-assembly with scaffolded DNA origami. Reproduced with permission from reference [40]. 
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Step 7: Single-particle based structural analysis. 
Single molecule microscopy techniques play an 
important role in the investigation of advanced DNA 
origami. They can be imaged by negative-stain 
transmission electron microscopy (TEM) and with 
atomic force microscopy (AFM) [30,32]. Alloyeau et al. 
showed that this is also possible for direct imaging 
along with chemical analysis of unstained DNA 
origami with transmission electron microscopy [52].  
DNA-based drug delivery 
Several DNA-based nanostructures, namely 
tetrahedral, icosahedral [53], nanotube [54–57], square 
and triangle [30] have been developed recently for in 
vivo and in vitro drug delivery applications. In 
contrast to dsDNA, DNA nanostructures could be 
internalized within the cells without any aid from 
transfection agents [58] and, when densely packaged, 
could be effectively used for the drug delivery 
purposes [59]. The cellular localization of DNA 
origami could be detected by fluorescence-based 
assays, which have the disadvantage of utilizing 
fluorescent labels. As alternative approach, Okholm et 
al. use quantitative real time polymerase chain 
reaction (qPCR) of M13 amplicons to quantify the 
cellular uptake of DNA origami structures [60]. In 
order to enhance and improve the cellular uptake/cell 
transfection of DNA-based systems, Mikkilä et al. 
demonstrated the possibility of coating DNA origami 
with virus capsid proteins, which can bind and 
self-assemble on the surface of origami through 
electrostatic interactions and pack the DNA 
nanostructures inside the capsid [61]. More recently, 
Brglez et al. designed an intercalator based on acridine 
derivatives that modify the surface properties of DNA 
nanostructures and increased the cell uptake 
compared to unmodified origami [62]. 
In Table 1, an overview of different applications 
of DNA nanostructures utilized for drug delivery is 
provided. Starting from DNA tiles, tetrahedral (N1) 
[63] and icosahedral (N2) [64] nanostructures were 
demonstrated to be effective for doxorubicin (doxo) 
delivery to breast cancer cells. In particular, the 
tetrahedral structure was found to be effective on 
drug-resistant cells. The icosahedral structure was 
able to efficiently deliver the doxorubicin in a targeted 
way only after functionalization with aptamer 
sequences against the tumor surface marker mucin 1 
(MUC1). DNA tetrahedral structures have also been 
shown to protect single-strand sequences against 
nuclease degradation; in particular, this kind of 
structure has been employed to increase the in vivo 
circulation half-time of siRNA from 6 to 24 minutes 
(N3) [65] and deliver Cytosine-phosphate-Guanosine 
(CpG) to elicit an immunoresponse (N4) [66]. Finally, 
highly biocompatible aptamer-tethered DNA 
nanotrain (N5) against folic acid receptor exhibited 
high antitumor efficacy and reduced the side effects of 
doxo in a mouse xenograft tumor model [67]. Very 
recently, our group has demonstrated that a 
half-icosahedral nanostructure (N6) can efficiently 
delivery doxorubicin to breast and hepatic cancer 
cells. The study demonstrated the importance of the 
shape and structure of DNA nanostructures for 
biomedical applications [68]. 
 
Table 1. Overview of different DNA nanostructures and their applications. 
 Structure Characterization Biological activity  
N
° 
DNA 
Nanostruc-
ture 
Char-
acteri-
zation 
Size (nm) Cargo 
(Loading) 
Stability Target-
ing 
Loading 
efficiency 
Release Internalization In vitro tests In vivo tests Biodis-
tribu-
tion 
Ref 
Cells Activity Cells Activity 
1 Tetrahedral AFM 
DLS 
PAGE 
(6%) 
AFM: height 
2-3 nm DLS: 
9.08 nm ± 
3nm 
Doxo > 4 < 23 hrs 
Solution: 10% 
human serum 
Temp: 37°C  
 N/A 26 mole-
cules/ 
 structure 
Time: 1 hr 
Temp: N/A 
100% in 10hrs. 
<10% in 3hrs. 
Solution: PBS 
pH 7.4 Temp: 
37°C 60% in 10 
hrs Solution: 
PBS pH 5 Temp: 
37°C  
Macropinocyto-
sis and caveolae- 
mediated 
endocytosis 
pathways 
Breast cancer MCF7 
(drug sensitive) 
and MCF7-ADR 
(Doxo resistant).  
Doxo-tetrahedral is 
more effective on 
cell viability of 
MCF7-ADR than 
free doxo. Same 
efficacy on MCF7 
cells. 
N/A N/A N/A [63] 
2 Icosahedral: 
five- (120 bp) 
and six- (144 
bp) (aptamer) 
point-star 
structure 
AGE 
(2%) 
DLS 
TEM 
DLS: - Five 
stars (28.2 nm 
± 3nm) - Six 
stars (28.6 nm 
± 5nm). TEM: 
25 nm 
Doxo >30min Solu-
tion: cell culture 
medium Temp: 
37°C 
Mucin 1 
(MUC1)
. Tumor 
surface 
marker 
1200 molecu-
cu-
les/structure 
Time: 1h 
incubation 
Temp: room 
temperature 
N/A Dynamin- 
dependent and 
clathrin- 
mediated 
endocytosis. 
Degradation in 
lysosomes 
Breast cancer MCF7 
(MUC1+), CHO-K1 
(MUC1-) 
Doxo-Aptamer 
six-point-star 
structure is more 
effective on cell 
viability of MUC1+ 
cell than free doxo. 
Same efficacy on 
MUC- cells. 
 N/A N/A N/A [64] 
3 Tetrahedral 
(30bp/edge, 
Total 6 edges) 
AFM 
DLS 
PAGE 
(5%) 
AFM: height 
7.5 nm. DLS: 
28.6 nm ± 
2.38 nm 
siRNA 
against 
GFP gene. 
DNA 
structure 
conjugated 
with folic 
acid.  
N/A Folic 
acid 
receptor 
(FAR) 
1-6 siRNA per 
tetrahedral (1 
siRNa/edge) 
 N/A  N/A HeLa cells (LUC+). 
KB cells (HeLa cell 
contaminant 
overexpressing 
folate receptor) 
HeLa: LUC expres-
sion < 50%. KB: 
GFP expression 
<40%  
KB xeno-
graft 
tumours  
siRNA no effect 
on LUC. siR-
NA-DNA- 
tetrahedral: IC 
50 LUC expres-
sion: 1.8 mg/kg. 
Inj: intratumor 
or tail-vein 
Stability: siRNA 
6 min; siR-
NA-DNA 
tetrahedral 24 
min. 
Tumor, 
Kidney 
Time: 
12 
hours 
post 
injec-
tion 
[65] 
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 Structure Characterization Biological activity  
N
° 
DNA 
Nanostruc-
ture 
Char-
acteri-
zation 
Size (nm) Cargo 
(Loading) 
Stability Target-
ing 
Loading 
efficiency 
Release Internalization In vitro tests In vivo tests Biodis-
tribu-
tion 
Ref 
Cells Activity Cells Activity 
4 Tetrahedral PAGE 
(3.5%); 
N/A Straptavi-
din (STV) 
and CpGs 
5hrs Solution: 
FBS 50% Temp: 
room tempera-
ture 
N/A N/A N/A Endocytosis. 
Antigen local-
ized in lyso-
somes after 2 
hours 
RAW264.7 (mac-
rophage, Abelson 
murine leukemia 
virus transformed). 
Increased internal-
ization of the 
complex tetrahe-
dron-STV-CpG by 
APC cells  
BALB/c 
immuno-
competent 
mice 
Mice immunized 
with the com-
plex tetrahe-
dron-STV-CpG 
developed a 
stronger and a 
longer immuni-
tary response. 
N/A [66] 
5 Aptam-
tam-
er-tethered 
DNA na-
notrain 
AFM 
AGE 
(3%) 
TEM 
AFM: length 
100 nm. 
Doxo, 
epirubicin, 
dauno-
rubicin 
>45 hrs Solu-
tion: PBS + 5mM 
Mg2+ Temp: 
N/A 
Protein 
Tyrosin 
Kinase 
7 
(PTK7) 
N/A N/A Endocytosis CEM cells (human 
T-cell acute lym-
phocytic leukemia 
PTK7+) and Ramos 
(human B lym-
phocyte Burkitt’s 
lymphoma PTK7-) 
Drug-Aptamer-DN
A-drug is more 
cytotoxic on PTK7+ 
cells than free drug. 
Same efficacy on 
PTK7- cells. 
CEM 
(PTK7+) 
xenograft 
mouse 
model 
Increased 
antitumor 
efficacy and 
reduced side 
effects of doxo 
delivered via 
Aptamer-DNA 
nanotrain. Inj: 
I.V. 
  [67] 
6 Open Caged 
DNA (py-
ramidal), 408 
bp 
PAGE 
(7%) 
N/A Doxo 35 hrs (half-life) 
Solution: cell 
culture medi-
um+10% FBS 
Temp: 37°C 
N/A 172 molecules 
doxo/structu
re (at 15% of 
loading 
efficiency) 
50% of Doxo 
release from 
py-Doxo in PBS 
in 5 hrs and 3 hrs 
in FBS. Free 
Doxo in 20 
minutes 
py-Doxo is able 
to penetrate 
inside 
MDA-MB-231, 
release Doxo in 
the nucleus 
MDA-MB-231, 
HepG2 
Decrease cell 
viability compared 
to free doxo 
N/A N/A N/A [68] 
7 Tube with 
different 
global twist 
(Straight (S) 
10.5 bp/turn 
and Twist (T) 
tube 12 
bp/turn) 
AGE 
(2%) 
TEM 
TEM: length: 
138 nm, 
diameter: 13 
nm 
Doxo 48hr (T-tube) 
Solution: 10% 
FBS Temp: 37°C 
 N/A N/A 80% (T-tube) 
and 90% (S-tube) 
in 10 hrs Solu-
tion: PBS pH 7.4 
Temp: 37°C 
N/A Breast cancer 
MDA-MB-231; 
MDA-MB-468; 
MCF-7 
In all the cell lines 
tested the T-DNA 
IC50 is ≈2 times 
lower than free 
Doxo. (calculated 
by our group) 
N/A N/A N/A [70] 
8 Tube AGE 
(2%) 
TEM 
TEM: length: 
80 nm, 
diameter: ≈20 
nm 
62 CpG 
sequence 
specific for 
mouse Toll 
like 
receptor 9  
6 hrs Solution: 
cell culture 
medium Temp: 
37°C 
Toll like 
receptor 
9 
(TLR9). 
62 binding 
sites per tube 
 N/A N/A Splenocytes from 
female C57BL/6 
mice 
N/A Immu-
noresponse 
through the TLR9. 
Nontoxic 
N/A N/A N/A [71] 
9 Hexagonal 
barrel with 
ap-
tamer-based 
lock (antigen 
keys). 
AFM 
AGE 
(2%) 
DLS 
TEM 
DLS: 90 nm 
TEM: 35nm x 
35 nm x 45 
nm  
Fab 
antibody 
fragments  
N/A CD33, 
CDw32
8 
 N/A  N/A  N/A NKL Increase apoptosis N/A N/A N/A [72] 
10 Triangle and 
tube 
AFM 
AGE 
(1%) 
AFM: 
-Triangle: 
edge ≈ 150nm 
-Tube: length 
≈ 183 nm 
Doxo N/A N/A  >200000 
molecules 
(calculated by 
our group) 
Time: 24 hrs 
Temp: room 
temperature.  
≈15% pH 7.4, 
35% pH 5.5 in 48 
hrs ≈25% in 
MCF7 cell lysate 
>40% with 50U 
DNAaseI 
Solution: PBS 
Temp: 37°C 
Endocytosis and 
localization of 
origami in 
lysosomes after 
6 hours of 
treatment. 
Breast cancer MCF7 
and MCF7 resistant  
MCF-7: 2.5µM and 
MCF-7 resistant 
>100μM. DNA 
origami loaded 
with doxo en-
hanced the cells 
death compared to 
free doxo on MCF7 
doxo resistant cells. 
No differences 
between free doxo 
and origami doxo 
in regular MCF7.  
N/A N/A N/A [73] 
11 Tube, trian-
gle and 
square  
AFM 
AGE 
(1%) 
DLS 
AFM: -Tube: 
height: 7 nm, 
diameter: 380 
nm, 
-Triangle: 
edge 120 nm, 
-Square: 
length*width 
90nmx60nm 
DLS: 
-Triangle: 59 
nm -Square: 
80.9 nm 
-Tube: 98.6 
nm.  
Doxo 24 hrs Solution: 
serum Temp: 
37°C 
N/A  >200000 
molecules 
(calculated by 
our group) 
Time: 24 hrs 
Temp: room 
temperature.  
≈20% of Doxo is 
released in 48 
hours at pH 7.4, 
≈35% is released 
at pH 5.5 Solu-
tion: PBS Temp: 
37°C 
N/A Breast cancer 
MDA-MB-231  
No significant 
difference com-
pared to the free 
doxo. 
MDA-MB-
231 cells 
Orthotopic 
breast 
cancer 
model  
Increased EPR 
effect of DNA 
origami. Signifi-
cant tumor 
reduction in 
mice treated 
with 
doxo-origami 
compared to free 
doxo Inj: I.V 
Tumor: 
Trian-
gle > 
tube 
>squar
e 
Tumor 
> liver 
> 
kidney 
> 
spleen 
Time: 
24 hrs 
[74] 
12 Tube (Tile) AGE 
(2%) 
TEM 
TEM: Length: 
27 nm and 
diameter: 8 
nm 
siRNA 
(GFP) 
8hrs Solution: 
cell culture 
medium Temp: 
37 °C (Degrada-
tion depends on 
Mg2+ concentra-
tion, oligonucle-
otide sequences, 
salt concentra-
tion, structural 
extension)  
Folic 
acid 
receptor 
(FAR) 
N/A N/A Endosomal 
trapping (no 
release) 
N/A No effects on GFP 
expression 
N/A NA NA [86] 
AGE: Agarose gel electrophoresis. PAGE: Polyacrylamide gel electrophoresis. TEM: Transmission electron microscopy. DLS: Dynamic light scattering. AFM:  Atomic force microscopy. N/A: Not 
Applicable. Temp:  Temperature. Inj: Injection. I.V.: Intravenous. Luc: Luciferase 
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Figure 7. Schematic design of the DNA carrier-drug complex. A) Long, single-stranded DNA scaffold (M13mp18 phage genomic DNA, blue) hybridizes with rationally designed 
helper strands to fold into triangular, square, and tube origami shapes. The biodistribution of unstructured M13 DNA and different nanostructures of DNA origami was 
investigated in subcutaneous breast tumor model. After in vivo biodistribution, the triangle-shaped DNA origami demonstrated optimal tumor accumulation; it was then used for 
doxorubicin intercalation. The Watson-Crick base pairs in the double helices of DNA origami serve as docking sites for doxorubicin intercalation (DOX/DNA origami, red). B) 
Tail-injected DOX/DNA origami complexes were delivered via blood circulation, accumulating in the breast tumor of nude mice because of EPR effects. Reproduced with 
permission from reference [74]. 
 
DNA origami, which provides enhanced size, 
dense packaging of strands and controllable shape, 
can be used to construct multivalent and 
multifunctional drug carriers. DNA origami was 
found to be stable in cell lysates and can be slowly 
degraded in living cells after 72 hours of treatment, 
demonstrating its great potential for controlled drug 
release [69]. This property was demonstrated in an in 
vitro experiment by Högberg group. The authors were 
able to control the kinetics of the release of doxo from 
DNA origami tubes (N7) by regulating the global 
twist of the structure, showing that the twisted form 
releases doxo more slowly than the normal structure 
[70]. The Liedl group constructed a 30-helix DNA 
origami nanotubes (N8) that were functionalized with 
CpGs oligonucleotides (up to 62 molecules) and tested 
for their immunostimulatory efficacy in isolated 
mouse spleen cells. Splenocytes include a subset of 
immune cells such as dendritic cells and macrophages 
that initiate and control the immune response. 
CpG-DNA nanotubes are internalized better than 
CpG alone and consequently stimulate a strong 
immune response [71]. DNA barrels (N9) have been 
constructed in a structure capable of selectively 
interfacing with cells to deliver signaling molecules to 
cell surfaces [72]. The opening lid is based on a DNA 
aptamer-based lock mechanism, which opens in 
response to the binding of antigen keys. 
Different DNA nanostructures, namely, triangle, 
square and tube, were synthesized and tested for drug 
delivery in in vitro and in vivo experiments (Figure 7) 
[73,74]. In vivo experiments demonstrated that these 
structures were able to deliver doxo efficiently to 
normal and resistant cancer cells [74]. Interestingly, it 
appears that the triangular structure resided in the 
tumor for a significantly longer time than the square 
and tube structures (N10 and N11). This might be 
attributed to the different shape of DNA structures 
and was probably due to the enhanced retention time 
inside the tumor (Figure 7). In most studies, drug 
loading on DNA nanostructures relies on the 
intercalation property of doxo molecules with base 
pairs of DNA duplex [70,73,74]. High loading 
efficiencies of doxo with different DNA origami 
structures have been achieved. For instance, in the 
case of DNA tube, more than 70% loading efficiency 
was obtained [73].  
Due to the programmed and well-defined 
properties of DNA nanostructures, it is possible to 
precisely control the spatial distribution of cargo 
molecules over DNA structure. In fact, there is 
virtually no limit for tethering DNA with various 
functional molecules through covalent modifications. 
DNA oligomers with a large variety of functional end 
groups are commercially available. Amino- 
functionalized DNA has been employed to bind 
carboxylic groups, and thiol-modified DNA to 
maleimide groups [75]. Srinivasan et al. have 
developed a novel procedure for labeling plasmid 
DNA using quantum dots (QDs) [75]. This method 
involves covalent conjugation of plasmid DNA to 
phospholipid/polyethylene oxide-encapsulated 
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cadmium selenide/zinc sulfide (CdSe/ZnS) 
core/shell QDs using a peptide nucleic 
acid–N-succinimidyl-3-(2-pyridylthio) propionate 
(PNA–SPDP) linker, which facilitates tagging of the 
plasmid without interfering with its function. 
QD-tagged DNA can transfect cells with high 
efficiency and intracellular trafficking can be followed 
through time. The “tagged” DNA plasmid remains 
functional and serves as a template for gene 
transcription upon internalization in the nucleus. 
The avidin-biotin system has also been used as a 
non-covalent receptor-ligand system for the binding 
of DNA to nanoparticles like gold nanoparticles 
(AuNPs) or quantum dots (QDs) [76,77]. Other than 
covalent modifications, DNA is negatively charged 
and is essentially a polyelectrolyte molecule which 
could bind through the positive charge of the surface 
such as gold nanoparticles with quaternary 
ammonium [78]. Additionally, it has been 
demonstrated that DNA incubated at high 
stoichiometric excess over gold nanoparticles shows 
nonspecific adsorption [79]. 
Issue of Concerns 
Characterization (Table 1, column 3) 
The assembly of DNA nanostructures was 
characterized by multiple techniques, including 
agarose (AGE) or polyacrylamide gel electrophoresis 
(PAGE), transmission electron microscopy (TEM), 
dynamic light scattering (DLS) and atomic force 
microscopy (AFM). 
The AGE/PAGE techniques are performed by 
applying an electric field allowing DNA migration 
through an agarose or polyacrylamide matrix. The 
nanostructures are separated by size (shorter move 
faster than longer structures) and analyzed under 
UV-light after staining with ethidium bromide. The 
nanostructures can be extracted from the gel and 
dissolved in a suitable buffer. The yields of assembled 
DNA nanostructures can be estimated by running an 
agarose or polyacrylamide gel and comparing the 
intensity of the bands to a standard reference [64,65]. 
When the structures are loaded with drugs, the DNA 
exhibits a decrease in folding quality compared to the 
sharp band before drug loading, as observed with a 
lower gel mobility, indicating that the drug was 
intercalated into the DNA [70,73]. 
Transmission electron microscopy (TEM) and 
atomic force microscopy (AFM) were used to 
demonstrate the assembly of DNA, the size, the shape 
and the monodispersity of the nanostructures. These 
techniques provide direct evidence of the morphology 
of nanostructures before and after drug loading 
[64,70,73]. Zhao et al. showed by using TEM images 
that twisted DNA nanostructures loaded with doxo 
were more compact, straighter and more elongated 
than the twisted DNA folded without doxo [70], while 
Jiang et al. demonstrated with AFM images before and 
after doxo loading that the morphology of the DNA 
nanostructure was retained after intercalation of the 
drug [73], and Douglas et al. utilized TEM to analyze 
the different states and conformations of DNA 
nanorobots [72]. 
The dynamic light scattering (DLS) technique 
was used to determine the hydrodynamic diameter of 
the nanostructures. It measures the fluctuations in 
scattered light intensity due to diffusing particles. 
When the system is monodisperse, the effective mean 
diameter of the particles can be determined. This 
measurement depends on the size of the particle core, 
the size of surface structures, particle concentration, 
and the type of ions in the medium. In general, the 
DLS measurement of the DNA nanostructures has 
shown a narrow size distribution, representing a 
uniform and monodisperse hydrodynamic size 
[63–65,74]. 
In Table 1, all the nanostructures are 
characterized by AGE/PAGE taking advantages of 
the simple and fast procedure to obtain information 
on the formation of nanostructures. These techniques 
were equally integrated with AFM or TEM analyses to 
demonstrate the size and shape of nanostructures. In 
this regard, there is uniformity and concordance 
among the papers helping with the interpretation of 
the results.  
Drug loading (Table 1, column 5) 
More than half of the studies have utilized doxo 
as proof-of-concept chemotherapeutic drug. 
Doxorubicin has the advantage of being widely 
utilized in cancer therapy, intercalates into DNA and 
has intrinsic properties such as fluorescence and 
absorbance that are of help during analysis. Other 
anthracycline chemotherapeutic drugs (e.g. 
daunorubicin (DNR), and epirubicin (EPR)) are 
widely used in therapeutic. They can preferentially 
intercalate non covalently into double-stranded 
5′-GC-3′ or 5′-CG- 3′ [67,80]. The platinum drugs, such 
as cisplatin, carboplatin, and oxaliplatin, bind to the 
nitrogen (N) position of the two adjacent guanine (G) 
bases of DNA, which is responsible for the cytotoxic 
effect of platinum drugs [81]. Wang et al. designed a 
cationic core-shell nanoparticles with a hydrophobic 
core and a cationic shell by self-assembly process from 
a biodegradable copolymer. A hydrophobic drugs, 
such as Paclitaxel (PTX), can be incorporated into the 
core during the self-assembly and the cationic shell of 
the PTX-loaded nanoparticles bind to the DNA by 
electrostatic interaction between the negative charge 
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of DNA and the positive charge of the nanoparticle 
[82]. In addition to the non-covalent interaction, the 
chemotherapeutic drugs can covalently functionalize 
the DNA. Each DNA origami staple strand is 
synthetically made and can be modified in predefined 
positions and incorporating different functions (e.g. 
amino groups). For example, the methotrexate (MTX), 
a chemotherapeutic drug, can be functionalized 
covalently to the surface of DNA by a chemical 
reaction between the amino group of DNA and the 
carboxylic group of the MTX in the presence of EDC 
(1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide) 
used as carboxyl activating agent for the coupling of 
primary amines to form amide bond.  
Since the field of DNA nanotechnology is in its 
infancy, no comparison with other drug delivery 
systems has been done. Liposomal formulation of 
doxorubicin (Doxil®), one of a few examples of 
success in clinic [83–85] represents a gold standard to 
be compared. Although doxo offers many advantages 
as cargo, others drugs should be tested to understand 
whether DNA origami could be applied to different 
chemotherapeutic treatments. Targeted therapy is 
now at the forefront of cancer therapy and is based on 
the application of monoclonal antibodies (e.g. 
Herceptin, an anti-HER2) or small molecules (e.g. 
Gifitinib, an anti-EGFR) directed against specific 
targets. In contrast to doxorubicin, these molecules do 
not have intercalation properties, thus they should be 
incorporated on the surface of DNA origami through 
covalent and non-covalent linkers or be loaded inside 
a DNA origami cage structure. In the last case, logic 
gate cages of different shapes and dimension should 
be designed to entrap the molecules [72]. In this 
regard, a DNA nanorobot was demonstrated to 
deliver antibodies against human CD33 and CDw328 
to induce growth arrest of natural killer cells as well 
as antibodies targeting human CD3e and flagellin to 
induce T cell activation [72]. Other cargos such as 
siRNAs [65] or specific DNA sequences [66,71] could 
be loaded to obtain gene-specific downregulation or 
elicit an immune response, respectively. The data 
support the DNA nanostructures as multivalent DDS, 
which could be adapted for any particular 
requirement. 
Stability (Table 1, column 6) 
A stability test of the DNA nanostructure used as 
a drug carrier has been carried out in most the studies. 
Stability was found to be strictly dependent on the 
type of solution, that has been utilized and the 
temperature. Although in most cases the experiments 
were done at 37 oC corresponding to the physiological 
temperature of the human body, in a few papers the 
experiment was carried out at room temperature or 
the temperature was not reported. With regard to the 
media, there is less concordance. Cell culture media or 
fetal bovine serum has been utilized at different 
concentration or physiological solution such as 
phosphate buffer (PBS). In this regard, Kocabey et al. 
reported that degradation depends on Mg2+ 
concentration, oligonucleotide sequences, salt 
concentrations and whether structural extensions (e.g. 
sequences to integrate aptamers) were utilized (N12) 
[86]. In the light of these observations, a careful 
analysis should be conducted and actually, it is 
difficult to draw firm conclusions. 
In general, DNA-origami-based structures depict 
higher stability (more than 24 hours) in physiological 
buffer as well as in serum. In contrast, non-origami 
DNA nanostructures exhibit lower stability. The 
higher density of double helices in DNA-origami 
nanostructures is likely the main factor contributing 
to their stability [74]. However, in vivo stability 
information about DNA nanostructures is still 
inadequate. Recently, Lee et al. determined that the 
half-life of siRNAs hybridized to a DNA tetrahedron 
(1 siRNA/edge) increased the circulation time from 6 
to 24 minutes in the blood [65]. These observations 
showed that the stability of DNA nanostructures is 
still the critical factor undermining their potential 
clinical applications. The entrapment of siRNAs 
inside lipid nanoparticles (LNP) has been useful in 
overcoming degradation and cell permeability 
problems related to RNA interference [87]. On the 
other hand, LNP-siRNA could be entrapped inside 
the endosomes reducing the efficacy of treatment [88]. 
Conjugation of siRNAs with polymers could 
overcome this problem [89]. Nonetheless, the easy 
custom synthesis of DNA with any arbitrary sequence 
allows the insertion of modified bases and 
non-natural chemical modifications at specific 
positions of the synthetic DNA strands, which could 
be utilized to tune their in vivo stability along with 
imparting additional functionalities. The high 
chemical versatility that allows the easy addition of 
targeting ligands represents a significant advantage of 
DNA nanostructures compared to other DDS.  
Loading efficiency (Table 1, column 8) 
Concerning chemotherapeutic drugs, the 
loading efficiency is influenced mainly by the DNA 
origami and drug concentration, the incubation time 
and the reaction temperature. In a few papers, all 
these parameters have been reported. We have 
estimated that the number of doxo molecules per 
DNA nanostructure was between 26 and more than 
200,000 molecules. Although the dimension of the 
structure and the number of DNA strands are 
different, the theoretical maximal numbers of doxo 
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molecules that could be intercalated inside the 
structure does not always correspond to that observed 
and an overloading of the DNA nanostructure could 
often be foreseen. Over-saturation of nanostructures is 
not an ideal condition for in vivo experiments and, 
may lead to deformation of the nanostructure itself 
[90], unspecific effects, and altered uptake kinetics 
and artifacts. Doxo is known to undergo 
self-association in aqueous solution, which may alter 
the binding and release properties of doxo from the 
nanocarrier [91,92]. 
The loading efficiency was one of the major 
problems of liposomes. To be used in clinic, the 
drug/liposome (weight/weight) ratio should be more 
than 70% to avoid a high concentration of lipids in 
circulation. An active remote loading was developed 
that works perfectly with doxo and could be utilized 
for weak basic or acid amphipathic molecules [93]. 
Inside the liposome, the high concentration of 
ammonium sulfate allows the precipitation of 
doxorubicin. This process produces a stable gradient 
of doxorubicin between outside and inside the 
liposome, which allows an efficient drug loading [94]. 
A hybrid system formed from the encapsulation of 
DNA nanostructures by a lipid membrane has been 
suggested to improve the stability of the 
nanostructures in biological environments, and avoid 
the activation of inflammatory immune response for 
the in vivo application. The development of this 
hybrid system has focused on increasing the 
bioavailability and targeting of anticancer agents [95].  
Release (Table 1, column 9) 
Besides physiological stability, another 
important factor is the control and tuning of the 
release of the drug cargo from DNA nanostructures. 
Most of the studies have performed the release tests in 
PBS at different pH or in cell lysate solutions. It has 
been observed that there are big differences in the 
drug release depending on the DNA structures. The 
DNA tetrahedral, icosahedral and tube release most 
of the doxorubicin in 10 hours. On the other hand, a 
DNA triangle, square but also a tube of different sizes 
(183 nm for N10 and 380 nm for N11) take more than 
48 hours to release about only 20% of drug in PBS 
solutions. In this case, parameters such as different 
experimental conditions (the release of doxo increased 
when the pH decreased from 7.4 to 5.5 suggesting that 
the release of doxo increases when the 
doxo-intercalated DNA is retained in the acidic tumor 
region), sequences, salt concentration and structural 
shape (tetrahedral origami with 9 nm (N1) releases 
100% of doxo in 10h, a tube structure of 138 nm in 
length (N7) releases 80-90% of doxo in 10h and a 
triangular shape of 150 nm per edge (N10) and (N11) 
releases 20% of doxo in 48h) and density may 
influence the results.  
Zhao et al. used a very interesting approach to 
control the release kinetics of doxorubicin from DNA 
tubes. They designed DNA origami tubes with 
different global twists through which they were able 
to tune the encapsulation efficiency and the doxo 
release rate [70]. They synthesize two types of DNA 
origami. The first one was a straight nanotube 
(S-Nano) with 10.5 bases per helical turn of DNA. The 
second one was a twisted nanotube (T-Nano) with 12 
bases per helical turn. The release rate of doxo from 
the structures was studied by measuring the doxo 
fluorescence. The T-Nano retains the drug and 
exhibits a slower release profile (50% of doxo remains 
bound to the T-Nano after several hours). The 
encapsulation efficiency of the two structures of DNA 
showed that the T-Nano encapsulates more doxo per 
structure than the S-Nano (33% higher for T-Nano 
than S-Nano). This could be explained by the fact that 
the T-Nano contains more base pairs per structure (12 
bp/turn) and a higher affinity for doxo due to the 
relaxation of the DNA structure when doxo is 
intercalated [68]. 
In vitro activity (Table 1, columns 11 and 12) 
All the studies reported the activity of DNA 
nanostructures on cell culture. Since doxo is the most 
utilized drug, breast cancer cell lines were chosen. The 
efficacy of DNA-doxo complex was evaluated in cell 
viability and cytotoxicity experiments. DNA origami 
increased the efficacy of doxo and when evaluated for 
cell internalization, the endocytotic pathway was the 
principal entry route into the cell.  
An in-depth analysis will be necessary to clarify 
the fate of different DNA nanostructures. Approaches 
such as RNA interference or chemical inhibitors could 
be used to assess the mechanism of subcellular 
redistribution, recycling and excretion of the DNA 
structure. For example, it has been demonstrated that 
endocytic recycling restricts siRNA delivery with 
lipid nanoparticles but little is known about the 
delivery through DNA nanostructure. Multiple cell 
signaling effectors are utilized for nanoparticle 
cellular internalization but gene knockdown effects 
are almost abrogated by recycling pathways with 
specific proteins involved in the process [96]. The 
authors suggested that siRNA delivery efficiency 
might be improved by designing delivery vehicles 
that can escape the recycling pathways, an aspect that 
is not primarily kept in consideration. 
In vivo activity (Table 1, columns 13, 14 and 15) 
The in vivo application of DNA nanostructures 
has been limited by the relative structural instability. 
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However, in the few cases tested, DNA 
nanostructures have been shown to improve the 
pharmacological effect of their cargo. siRNAs are 
more stable in the blood ameliorating the knockdown 
efficiency [65] or CpG DNA sequences can elicit a 
longer immune response [66]. In regard to 
chemotherapeutic drugs, DNA tiles and DNA origami 
have shown increased doxorubicin efficacy in tumor 
growth assay in xenograft mouse models. 
Interestingly, all the structures accumulate 
specifically in the tumor most probably taking 
advantage of the well-known EPR effect. Among 
DNA origami, the best activity was obtained by the 
triangular structure, highlighting that the shape of the 
structure of DNA origami also has a prominent role in 
the activity in vivo. Preliminary biodistribution studies 
have shown that the liver, kidney and spleen are 
primary organs for DNA nanostructure accumulation 
[65,74]. Up to now, no studies on pharmacokinetics 
and pharmacodynamics profiling have been carried 
out. In our opinion, this point is crucial for 
understanding the applicability of DNA in the field of 
therapy. We need to keep in mind that the in vitro 
efficacy of PEGylated liposomal doxo was two times 
lower than that of free doxo. The high stability of 
Doxil® slowly releases the drug in cell culture, which 
turn out to be an advantage in vivo by increasing the 
EPR effect in the tumor [97]. Multiple time points after 
the administration of a drug in animal models allow 
for complete pharmacokinetic and 
pharmacodynamics analysis. The parameters 
typically provided include drug concentration over 
time, area under the curve (AUC), elimination 
half-life, clearance, time of maximum concentration, 
and volume of distribution, which are useful for 
characterizing the pharmacokinetics properties of the 
drug associated with the nanocarrier [98]. Moreover, 
specific drug dosage investigations have to be 
designed to evaluate the origami effects in vivo over 
an extended period of time. Dose administration at 
one or several time points could be used to evaluate 
overall toxicity in the animal model and the effects on 
tumor growth. 
DNA nanostructures are foreign materials that in 
theory should be considered as non-self, which could 
be recognized from the DNA sensing machinery and 
consequently degraded. DNA is normally confined in 
the nucleus. When DNA accumulates in the 
cytoplasm or in endosomes, it is recognized as 
"anomalous" material. Classical B-form DNA could 
stimulate immune response through the Toll-like 
receptor (TLR) pathway. In the endosomes of 
dendritic cells, TLR9 is activated by anomalous DNA 
and elicits Type I interferon response. TLR9 
preferentially binds unmethylated CpG-rich DNA. 
These DNA sequences are abundant in numerous 
pathogen genomes and their binding to the 
endosomal TLR9 stimulates immune response. In the 
cytoplasm, cells are embedded with DNases, which 
degrade foreign DNA [99]. Cyclic GMP-AMP 
synthase (cGAS) and absent in melanoma 2 (AIM2) 
are a group of sensors that detect DNA in a 
sequence-independent manner and are localized in 
the cytoplasm. There is a third group of DNA sensors 
localized both in nucleus and cytoplasm including 
interferon-inducible genes 16 (IFI16), RNA 
polymerase III and the Mre11-Rad50-Nbs1 (MRN) 
complex. The first hurdle that DNA meets in the 
blood stream is a few enzymes capable of degrading 
it, such as deoxyribonuclease II, phosphodiesterase I, 
DNA hydrolyzing autoantibodies, and neutral 
deoxyribonuclease I, which is responsible for more 
than 90% of deoxyribonuclease activity in blood 
plasma [100]. DNase I is a secreted protein that is 
released into the alimentary tract and bloodstream. It 
acts on single-stranded DNA, double-stranded DNA, 
and chromatin producing fragments of various 
lengths [101].  
It has been demonstrated that compact 
structures of DNA present a decreased enzymatic 
recognition compared to linear DNA. Keum et al. 
[102] assembled a tetrahedron with edges of about 7 
nm containing a centrally located enzyme restriction 
site, CTNAG (DdeI). It was demonstrated that the 
tetrahedron structure is less sensitive to DdeI cleavage 
than the linear DNA presenting the same restriction 
site. This was probably due to the increased 
mechanical stability of the ligated DNA. The 
resistance to non-specific degradation by DNase I was 
also tested. The tetrahedron structure was digested 
more slowly than the linear fragment. The 
explanation of this difference could be attributed to 
the sensitivity of DNase I activity to local and global 
helix geometry, which are different between 
tetrahedral and linear structures. To mimic the 
physiological condition, the stability of the 
tetrahedron structure was tested in the presence of 
10% FBS. The structure was more resistant to endo- 
and exo-nuclease cleavage in the serum. The 
degradation indicated a first-order kinetics and the 
decay time constant differed by nearly a factor of 50: 
0.8 hours for the linear DNA and 42 hours for the 
tetrahedron. The authors hypothesized that the size is 
an important feature to confer resistance to the 
enzymatic degradation, but other types of branched 
geometries, or curvatures, may also mean protection 
factors. 
To overcome the host immunosurveillance, 
Perrault et al. developed a new system inspired by the 
envelope of viral particles. In particular, a DNA 
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octahedron of 50 nm was encapsulated in a lipid 
bilayer in order to mimic virus like particle. The 
octahedron structures are composed of bundles of six 
long double helices (28 nm) engineered with 90° 
curvatures. The DNA nanostructures could be 
functionalized by modifying the oligonucleotide 
structures with high precision. The lipid bilayer was 
directly assembled around the DNA octahedron, 
recruited by individual lipid-conjugated 
oligonucleotides preassembled onto the outer 
handles. Internal and external diameters were 53 and 
76 nm, respectively [95]. In vitro experiments 
demonstrated that encapsulated DNA drastically 
decreased the inflammatory response. The production 
of inflammatory cytokines IL-6 and IL-12 was evident 
only when the cells were treated with DNA 
octahedron but not when the structure was 
encapsulated. These results outlined that a three-stage 
DDS (Membrane-DNA-Drug) could increase the 
circulation half-life of the DNA nanostructures in the 
blood and finely control the drug release. In addition, 
the outer membrane could be engineered by adding 
specific molecules such as receptors, ligands or 
antibodies in order to target specific cells [95]. 
It will be a key step to understand the interaction 
between DNA sensing machinery and DNA origami 
to increase the performance as a delivery system. As 
for siRNA delivery with lipid nanoparticles [96] in 
which the recycling pathways are a limiting step for 
an efficient delivery, DNA immunosurveillance could 
play a fundamental role in the success of the DNA 
origami delivery system. 
Concluding remarks and outlook 
The discipline of DNA nanotechnology is 
founded on the unique and robust self-assembling 
properties of DNA through canonical complementary 
base pair interactions, which allow the programmable 
design of DNA nanostructures with the required 
anticipated geometry and functional properties. The 
modulation of size, shape and charge of DNA 
nanostructures has been shown to overcome the 
natural cell membrane barrier allowing the delivery of 
naked DNA or siRNA that otherwise would not enter 
the cells. DNA nanostructures could be easily 
programmed to be a smart container of different 
cargos of biomedical interest. Many circulating 
enzymes such as DNase represent a limitation of 
low-dense DNA nanostructures that especially in 
tumor cells are overrepresented. Dense packaging of 
DNA helices within a DNA nanostructure is one 
strategy that could increase their stability against 
DNA-degrading enzymes. Another approach could 
be to encapsulate DNA structures under a sheet of 
biocompatible materials like membranes, which will 
protect them from unspecific degradation [95,103]. 
From a therapeutic point-of-view, considering the 
elimination and terminal clearance half-life of most 
chemotherapeutic drugs, the in vivo half-life of 
DNA-based nanostructures should be higher than 30 
hours to enable their feasible clinical applications in 
drug delivery and formulation. For instance, the 
terminal clearance half-life of doxo, which is among 
the most widely used chemotherapeutic agents, is 
around 30 hours [104]. 
Another advantage of DNA origami could be 
represented by the ability to actively release multiple 
drugs. In the more mature field of liposomes, many 
research groups are dedicating much effort to loading 
different drugs inside a single liposome, especially for 
cancer therapy. As compared to DNA origami, the 
charge, hydrophobicity and pKa of the drug represent 
an important limitation for the loading of the 
liposome. The presence of a huge number of 
modifiable oligonucleotides ideally represents an 
advantage and easy way to load multiple drugs. 
Tweezer-like DNA nanodevices are able to control the 
activity of an external enzyme and represent an earlier 
system to be implemented to design a DNA 
nanomachine with intrinsic ability to actively release 
drugs [105]. 
The above studies showed that DNA 
nanotechnology could provide an excellent designing 
tool for the construction of novel drug delivery 
vehicles possessing optimum biocompatibility along 
with high cellular uptake kinetics of drug-loaded 
DNA nanostructures. DNA nanotechnology enables 
tuning and optimization for their best performance in 
in vivo and in vitro experiments by judiciously 
selecting the shape, size and functionalities of DNA 
nanostructures owing to the shape and 
size-dependent EPR effect. However, before in vivo 
applications of any perspective DNA nanostructure, a 
very careful and rigorous in vitro testing is required to 
avoid any misinterpretation or artifacts in the data 
[86]. In addition, the cost of production, the yield and 
purification steps is still an obstacle. Many 
laboratories are working in this direction and some 
improvements were recently achieved [46,105,106]. 
Nevertheless, the research area of DNA 
nanotechnology for drug delivery is still in the initial 
stage and a breakthrough is still needed in DNA 
nanotechnology, that could pave the way for the 
development of smart functional DNA origami for 
biomedical applications and drug delivery, and in the 
long term find a way to be translated into clinics to 
improve the health of patients.  
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